Part
01
of one
Part
01
How much % of Biotech/ Pharma companies are working on 1) Parkinson's Disease 2) neurodegenerative diseases and 3) neuroscience drugs?
Hi there, and thanks for asking Wonder! I understand you'd like an analysis of the percentage of global biotech and pharmaceutical companies who are currently working on Parkinson's disease, neurodegenerative diseases and neuroscience drugs. In short, after exhaustive research through market research reports and analyses, press releases, industry articles and academic databases, I have determined that the answer to your question is not available in public resources relative to the neurodegenerative diseases and neuroscience drug markets. However, my calculations indicate that fewer than 1% of biotechnology companies are working on Parkinson's R&D. Below you'll find my methodology and my relevant findings.
METHODOLOGY
By 'working on,' I understood the request details to mean 'working on research and development (R&D)." In an endeavor not to repeat information or strategies from the previous request, I have focused my research primarily on high-level market research reports and analyses, and statistical databases.
I reviewed my colleague's response for this query, and then began by researching the global number of pharmaceutical and biotech companies. This strategy discovered a Quora article which answered that question; and while we do not use Quora as a credible source, the article included a PDF link which provided a 2014 figure from OECD for the number of global biotechnology firms, which I have used as the basis for this figure.
I then research individually for preexisting market reports on the Parkinson's, neurodegenerative diseases and neuroscience drugs markets; and while my research discovered multiple paid market research reports and analyses for these markets, (examples here, here and here), none of the summary information indicates the number of companies involved in these markets.
Next, I researched for the number of companies involved in R&D for each of the requested market segments. This generated an 2016 'comprehensive' analysis of the Parkinson's pipeline which covered 179 companies; and while the market share of these companies is included in the paid report, it was not available in the free summary. This research strategy did not generate similar results for the neurodegenerative diseases and neuroscience drugs markets, nor any specific to 'pharmaceutical companies' distinct from biotech companies. Nearly all available sources focus on the 'top' segment of these markets, which is not useful for answering your question. Research through the Statista database also did not generate any useful statistical reports within its limited free samples and summaries.
RELEVANT FINDINGS
While I was unable to find a direct answer to your question, I have provided below all the data generated during my research which is relevant to your question.
PARKINSON'S MARKET
My research indicates that, as of 2014, there were 23,584 biotechnology companies globally. A little less than half were located in the US. While the market share of the 179 companies profiled in this 2016 report on the Parkinson's pipeline is not publicly available, we can reasonably assume that they represent nearly all of the market, since the report self-describes as 'comprehensive.' Therefore, we can further assume that, at least for Parkinson's, the percentage of biotechnology companies working on Parkinson R&D is less than 1%.
However, it should be noted that this figure for total biotechnology companies includes both public and private companies, and that all my research indicates that the private sector of this industry is both difficult to measure.
SUGGESTIONS FOR FUTURE RESEARCH
My research indicates that market research information with the specificity you are looking for would be most precisely obtained by conducting market research, which is usually commissioned through a market research firm. If you'd like us to research a list of such firms which might be a good fit for your needs, please let us know! We'll be happy to research that as a separate request.
CONCLUSION
To wrap it up: while extensive research did not generate sufficient information to calculate estimates or solid figures for the number of companies working in R&D in neurodegenerative disease and neuroscience drugs, my research indicates that the number of companies working in R&D for Parkinson's is less than 1%. Thanks so much for using Wonder! Please let us know if there is anything else we can research for you!